MX9700626A - Method of treating opportunistic infections with azaspiranes. - Google Patents

Method of treating opportunistic infections with azaspiranes.

Info

Publication number
MX9700626A
MX9700626A MX9700626A MX9700626A MX9700626A MX 9700626 A MX9700626 A MX 9700626A MX 9700626 A MX9700626 A MX 9700626A MX 9700626 A MX9700626 A MX 9700626A MX 9700626 A MX9700626 A MX 9700626A
Authority
MX
Mexico
Prior art keywords
azaspiranes
opportunistic infections
treating opportunistic
treating
mammal
Prior art date
Application number
MX9700626A
Other languages
Spanish (es)
Inventor
Alison Mary Badger
Peter John Bugelski
Danuta J Herzyk
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9700626A publication Critical patent/MX9700626A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Invented is a method of treating opportunistic infections in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a substituted azaspirane.
MX9700626A 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes. MX9700626A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414902A GB9414902D0 (en) 1994-07-23 1994-07-23 Methods
PCT/US1995/008915 WO1996003126A1 (en) 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes

Publications (1)

Publication Number Publication Date
MX9700626A true MX9700626A (en) 1997-05-31

Family

ID=10758802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700626A MX9700626A (en) 1994-07-23 1995-07-14 Method of treating opportunistic infections with azaspiranes.

Country Status (15)

Country Link
EP (1) EP0804201A4 (en)
JP (1) JPH10503202A (en)
KR (1) KR970704446A (en)
CN (1) CN1157564A (en)
AU (1) AU684384B2 (en)
BR (1) BR9508332A (en)
CA (1) CA2195778A1 (en)
CZ (1) CZ286482B6 (en)
GB (1) GB9414902D0 (en)
HU (1) HUT77379A (en)
MX (1) MX9700626A (en)
NO (1) NO310096B1 (en)
NZ (1) NZ290974A (en)
WO (1) WO1996003126A1 (en)
ZA (1) ZA956098B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9601909A (en) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N, n-diethyl-8,8-dipropyl-2-azaspiro (4,5) decane-2-propan amine dimaleate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
PT100566B (en) * 1991-06-07 1999-06-30 Smithkline Beecham Corp IMMUNOMODULATOR AZASPIRANES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION AND USE

Also Published As

Publication number Publication date
NO970284D0 (en) 1997-01-22
AU684384B2 (en) 1997-12-11
AU3190995A (en) 1996-02-22
CZ20997A3 (en) 1997-10-15
CZ286482B6 (en) 2000-04-12
HUT77379A (en) 1998-04-28
CA2195778A1 (en) 1996-02-08
NZ290974A (en) 1999-08-30
NO310096B1 (en) 2001-05-21
BR9508332A (en) 1997-11-04
HU9700201D0 (en) 1997-04-28
ZA956098B (en) 1996-05-23
JPH10503202A (en) 1998-03-24
WO1996003126A1 (en) 1996-02-08
GB9414902D0 (en) 1994-09-14
KR970704446A (en) 1997-09-06
CN1157564A (en) 1997-08-20
NO970284L (en) 1997-03-19
EP0804201A1 (en) 1997-11-05
EP0804201A4 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
PT880350E (en) MULTIPLE SCLEROSIS TREATMENT
MY113059A (en) Controlled-release dosage forms of azithromycin
ZA95463B (en) Use of interleukin-12 to prevent graft-versus-host disease
EA199800626A1 (en) APPLICATION OF PPAR-GAMMA AGONIST FOR THE TREATMENT OF SYNDROME X
EA200101089A1 (en) NEW METHOD OF TREATMENT
FI970747A (en) Combination product for use in immunological diseases
EE9700225A (en) A method of treating diabetes mellitus using KKF
MX9707875A (en) Levobupivacaine and its use as an anaesthetic in pregnant women.
IL131478A0 (en) Methods for treatment of scar tissue
MX9700626A (en) Method of treating opportunistic infections with azaspiranes.
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
BG102375A (en) Inoculation biocompatible hydrophilic gel, method for its preparation and application
MX9206135A (en) METHODS
LV11593A (en) The use of dimethicone in the treatment of constipation
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
EP0458537A3 (en) Therapeutic compound for the treatment of bronchitis
PL328949A1 (en) Method of treatng excessive aggression
MY118982A (en) Method of reducing tissue damage associated with ischemia
ES8500951A1 (en) Hydantoin therapeutic agents.
UA43389C2 (en) METHOD OF REDUCING SERUM CALCIUM LEVELS
MX9407703A (en) Method of treating septic shock using thymosin-alpha1.
UA15363A (en) Composition for treating open wounds
IL123382A0 (en) Preparation for the prophylaxis and/or treatment of wool and hair loss
UA18225A (en) Method for Treatment of wounds
MX9800365A (en) Treatment of acute leukemia with interleukin-10

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees